Clinical trials: Cirrhosis Liver
Cirrhosis, Sepsis
Cohort Study of Chronic Liver Disease Complicated by Sepsis
Study population: Patients with liver cirrhosis complicated by sepsis Observation indicators: Fluid resuscitation strategy, early dynamic indicators such as MAP Observation endpoint: 28-day all-cause mortality Study design…
- Trial name
- NCT07465003
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
COVID-19, Liver Cirrhosis
COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal.
- Trial name
- NCT04329559
- Where
- 15 sites in China
- Volunteers
- 21 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)
The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction…
- Trial name
- SCOUT Echo-AI (NCT07216859)
- Testing
- AI-Enabled Identification (EchoNet-Liver)
- Where
- 6 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Kaiser Permanente
Cirrhosis, Hepatic Encephalopathy
Effect of Music on Attention and Prospective Memory in Hepatic Encephalopathy
Hepatic encephalopathy (HE) is a potentially reversible, metabolically caused complication of acute or chronic liver diseases such as cirrhosis.
- Trial name
- NCT01882855
- Where
- United States
- Sponsor
- NYU Langone Health
Compensated Cirrhosis
Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis
Liver carcinoma is becoming the main complication of cirrhosis. Treatment of symptomatic or large tumors is disappointing. Regular ultrasonographic screening of small (curable) tumors is currently recommended, but the best…
- Trial name
- NCT00190385
- Testing
- Ultrasonographic screening
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, Liver Cirrhosis
Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)
Results of liver transplantation, the best theoretical treatment for HCC, are limited by tumor recurrence. In order to limit this risk Milan criteria was proposed in 1996.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Evidence of Liver Transplantation
- Trial name
- EFAPRE (NCT01198704)
- Testing
- search of factors predicting tumor recurrence
- Where
- France
- Volunteers
- 372 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
HCC - Hepatocellular Carcinoma, Cirrhosis
Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma
This is a single-centre, prospective cohort study. Consecutive patients with compensated liver disease and hepatocellular carcinoma (HCC) for curative-intent treatment will be invited to this study.
- Trial name
- NCT07036874
- Testing
- transient elastography and oesophagogastroduodenoscopy
- Where
- Hong Kong
- Volunteers
- 159 people
- Sponsor
- Chinese University of Hong Kong
Liver Cirrhoses
Concordance Between Echocardiographic Assessment Performed in the Initial Phase of Decompensated Cirrhosis With Edema and Ascites by an Expert Intensive Care Physician and a Non-expert Gastroenterologist
The investigators hypothesize that trans-thoracic ultrasound performed by non-specialist gastroenterologists with a standard training by intensive care doctors will give equivalent results to those achieved by experts for a…
- Trial name
- EchoCirrho (NCT03650660)
- Testing
- Trans-thoracic ultrasound
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Liver Cirrhosis
Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis.
The project is about evaluation of albumin and midodrine versus albumin alone in outcome of refractory ascites in patients with decompensated cirrhosis. Cirrhosis is a leading cause of disability and mortality worldwide.
- Trial name
- NCT04816240
- Testing
- Midodrine, Albumin, Standard Medical Treatment
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Alcoholic Hepatitis
Prothrombin Time Predicts Steroid Response in Severe Alcoholic Hepatitis.
Alcoholic hepatitis (AH) is the most severe form of acute alcohol-related liver disease. Maddrey's discriminant function (mDF) >32 defines the severe form of AH, which is associated with a high mortality.
- Trial name
- AH2023 (NCT05883891)
- Testing
- prothrombin time
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cirrhosis, Cirrhotic Cardiomyopathy
DOCICAR: Cardiac Dysfunction in Cirrhosis
Patients with cirrhosis have a altered cardiac response to stress. This study evaluate the cardiac response by MRI during dobutamine stress. Hypothesis: impared increase in cardiac output, cardiac index, ejection fraction.
- Trial name
- NCT00250315
- Testing
- Dobutamine
- Where
- Denmark
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Compensated Cirrhosis, Obesity
Effects of Weight Loss on Portal Pressure in Patients With Overweight/Obesity and Cirrhosis
Overweight/obesity is increasing both in the general population and in patients with cirrhosis. In compensated patients with cirrhosis increased BMI is a risk factor for clinical decompensation independent of liver function and…
- Trial name
- SPORTDIET (NCT01409356)
- Testing
- Diet + exercise
- Where
- 6 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Hospital Clinic of Barcelona
Decompensated Cirrhosis of Liver
GCSF Therapy in Decompensated Cirrhosis - A Double Blinded RCT
Cirrhosis of liver is a leading cause of morbidity and mortality worldwide. Complications like ascites, spontaneous bacterial peritonitis, variceal bleed, hepatic encephalopathy, hepatorenal syndrome (HRS) and hepatocellular…
- Trial name
- NCT03911037
- Testing
- G-CSF
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Diabetes Mellitus, Cirrhosis
Lyspro Insulin vs Regular Insulin in Cirrhotic Patients
OBJECTIVE: To compare lispro insulin and regular insulin in the glycemic control of patients with liver cirrhosis and type 2 diabetes subjects.
- Trial name
- NCT00513201
- Testing
- lyspro, regular insulin
- Where
- Italy
- Sponsor
- University of Campania Luigi Vanvitelli
Hepatitis C
Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C
Investigation of the effects of the new Abbvie direct acting anti-viral (DAA) treatment of chronic viral hepatitis C infection on the macrophage specific activation marker soluble CD163, portal hypertension determined by the…
- Trial name
- NCT02526641
- Testing
- Functional Hepatic Nitrogen Clearance (FHNC), Galactose Elimination Capacity (GEC), Liver vein catheterization
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- University of Aarhus
Cirrhosis
Recombinant Human Granulocyte Monocyte - Colony Stimulating Factor (GM CSF) for Prevention of Pneumonia in Patients With Cirrhosis
Informed consent obtained from the patient or the patient's legal surrogate. The window for randomization and initiation of study drug infusion is 2 days from day of Admission.
- Trial name
- NCT03123666
- Testing
- GMCSF
- Where
- India
- Volunteers
- 160 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Compensated Cirrhosis
Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV
This study will evaluate the safety and efficacy of combination treatment with grazoprevir + elbasvir for compensated cirrhotic participants with chronic genotype 1 (GT1) and genotype 6 (GT6) hepatitis C virus (HCV) infection…
- Trial name
- NCT03037151
- Testing
- Grazaoprevir/Elbasavir, Grazaoprevir/Elbasavir/RBV
- Where
- 2 sites in Thailand
- Volunteers
- 100 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Hepatitis C, Chronic, Liver Cirrhosis
Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)
The objective of the study is to evaluate the superiority of treatment with PegIntron and Rebetol over no antiviral therapy (control group) in subjects with chronic hepatitis C and type C compensated cirrhosis.
- Trial name
- NCT00811967
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Cirrhosis, Liver
Allopurinol and Quality of Life in Liver Cirrhosis
The study aims to evaluate the impact of allopurinol on patients' related quality of life.
- Trial name
- NCT05828836
- Testing
- Allopurinol Tablet
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University